OncoMed Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
OncoMed Pharmaceuticals' mission is to translate its founders' cancerous stem cell insights into novel medicines capable of eliminating the cancer stem cell and halting the spread of solid tumors. The company has identified about 50 proteins characteristic of cancer stem cells and has established a large library of antibodies capable of binding to them. It is also identifying small-molecule compounds that can halt these cancer stem cells.
You may also be interested in...
Cancer Stem Cell Differentiation In Reverse, Spontaneously
Scientists have now shown that both normal and cancerous mammary cells may spontaneously "de-differentiate" into stem cells without any genetic manipulations. This apparently innate cellular plasticity suggests new possibilities for utilizing cultured cells both as a tool in the discovery of cancer therapies that target cancer stem cells and also as an autologous therapy in regenerative medicine.
Start-Up Quarterly Statistics, Q4 2008
Highlights from the Q4 2008 review of start-up dealmaking: Fundraising in the biopharma, med-device, and in vitro diagnostics industries totaled $551 million, a 41% decrease from 3Q and just another indication of the tough economic times. Of the three acquisitions done this quarter--two in biopharma and one in devices--only one had a disclosed value. About one-third of the 19 biopharma alliances were in the cancer therapy area.
Start-Up Quarterly Statistics, Q4 2008
Highlights from the Q4 2008 review of start-up dealmaking: Fundraising in the biopharma, med-device, and in vitro diagnostics industries totaled $551 million, a 41% decrease from 3Q and just another indication of the tough economic times. Of the three acquisitions done this quarter--two in biopharma and one in devices--only one had a disclosed value. About one-third of the 19 biopharma alliances were in the cancer therapy area.